Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The ENVB news feed on Stock Titan aggregates company-issued press releases and other public updates so readers can follow how Enveric describes the progress of its pipeline, intellectual property estate, and capital markets activity.
Recent news from Enveric highlights several recurring themes. The company frequently reports on patent issuances and notices of allowance from the United States Patent and Trademark Office, including patents covering fused heterocyclic mescaline derivatives and N‑heterocycle substituted tryptamine derivatives within its EVM301 and EVM401 series. These announcements emphasize Enveric’s efforts to expand its portfolio of neuroplastogenic, non-hallucinogenic molecules and to strengthen composition of matter protection for potential treatments of neuropsychiatric and addiction disorders.
Another key category of ENVB news involves pipeline and preclinical development for the lead candidate EB‑003. Company updates have discussed preclinical models in post-traumatic stress disorder, dose range finding studies, chemistry and manufacturing work, and interactions with the U.S. Food and Drug Administration related to a planned Investigational New Drug submission. These items provide insight into how Enveric portrays the advancement of EB‑003 toward potential first-in-human studies.
Enveric also issues news related to financing and listing matters, such as warrant exercise inducement transactions, gross proceeds from warrant exercises, and actions taken in connection with Nasdaq listing requirements, including a reverse stock split. For investors and observers, these releases give context on how the company funds its operations and addresses exchange compliance.
By reviewing ENVB news on Stock Titan, readers can monitor Enveric’s own descriptions of its scientific progress, patent estate, financing transactions, and corporate developments over time. Investors who follow early-stage biotechnology companies may choose to consult these updates alongside the company’s SEC filings for a fuller view of the risks and plans Enveric outlines in its public communications.
Enveric Biosciences (NASDAQ: ENVB) announced a 1-for-50 reverse stock split effective July 14, 2022. This adjustment will reduce the outstanding shares from approximately 52.7 million to 1.05 million. Shareholders will not need to exchange certificates, as adjustments will be made automatically for shares held in brokerage accounts. This split is aimed at improving the company's stock price and maintaining its listing on the Nasdaq Capital Market. The company focuses on developing psychedelic-inspired mental health medicines.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on psychedelic-inspired mental health treatments, announced participation in three key conferences: the A.G.P. Summer Healthcare Conference on June 21-22, the Gravitas Los Angeles Summit on June 22, and the H.C. Wainwright Mental Health Conference on June 27. CEO Dr. Joseph Tucker will represent the company at these events, highlighting its commitment to developing innovative solutions for mental health issues affecting patients globally.
Enveric Biosciences (NASDAQ: ENVB) announced that President Avani Kanubaddi will participate in the virtual Microdose Psychedelic Capital Conference on May 26, 2022, at 4:05 p.m. ET. During the panel titled 'The Spinoffs - Divide and Conquer', topics will include recent spinoffs among publicly traded companies. Interested attendees can register here. For further inquiries or one-on-one meetings, contact KCSA Strategic Communications at EnvericBio@kcsa.com.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on psychedelic-inspired mental health treatments, will have CEO Dr. Joseph Tucker participate virtually in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. His presentation will be available on-demand starting May 24 at 7:00 a.m. ET. This event highlights Enveric's dedication to advancing mental health solutions, aiming to assist patients with conditions like PTSD and cancer-related distress. For further details or to arrange a meeting with management, interested parties should contact H.C. Wainwright.
Enveric Biosciences (NASDAQ: ENVB) announced plans to spin off its cannabinoid pipeline into a subsidiary, Acanna Therapeutics Inc., through a dividend to shareholders. This strategic move aims to create two separate biotechnology companies focusing on psychedelic-inspired mental health treatments and cannabinoid therapies. The spin-off is contingent on Acanna meeting Nasdaq listing qualifications and has secured $1 million in initial funding, with potential additional funding of $4 million upon completion. The goal is to enhance resource allocation and value creation for both companies.
Enveric Biosciences (NASDAQ: ENVB) is hosting a virtual fireside chat with Chief Medical Officer Dr. Bob Dagher on May 17, 2022, at 10:00 a.m. EDT. Dr. Dagher, with over 20 years of experience in neuroscience, will discuss the psychedelic industry and Cancer Related Distress, showcasing Enveric's unique approach to psychedelic therapeutics. He will also outline anticipated milestones for 2022. Interested participants can register for the event here.
Enveric Biosciences Inc (NASDAQ: ENVB) announced a dividend of one one-thousandth of a share of newly-designated Series C Preferred Stock for each outstanding share of common stock, effective for holders as of May 13, 2022. The Series C Preferred Stock will provide substantial voting rights and will be redeemable under specific circumstances. The company emphasizes its focus on developing psychedelic-inspired mental health medicines for conditions such as cancer-related distress and PTSD. Further details will be posted in a Form 8-K with the SEC.
Enveric Biosciences (NASDAQ: ENVB) announced its participation in three investor conferences in April 2022. Dr. Joseph Tucker, CEO, will speak at the Benzinga Psychedelics Capital Conference on April 19 at 11:10 a.m. ET in Miami, FL; the Sequire Cannabis & Psychedelic Conference on April 20 at 1:00 p.m. ET virtually; and the KCSA Psychedelics Investor Conference on April 27 at 11:00 a.m. ET, also virtually. Interested attendees can register for these events through the provided links.
Enveric Biosciences (NASDAQ: ENVB) reported a comprehensive net loss of $48.8 million for the year ending December 31, 2021, up from $7.0 million in 2020. The loss per share was $2.07. The company ended 2021 with $17.4 million in cash and equivalents. Key milestones included the acquisition of MagicMed and positive preclinical data for EV102. Enveric also filed several patent applications to strengthen its intellectual property portfolio and closed a $10 million public offering to support its drug development efforts.
Enveric Biosciences (NASDAQ: ENVB) has filed a provisional patent application for over 100 novel molecules, potentially leading to 10,000 new drug candidates. This initiative is part of their second-generation program targeting cancer-related distress (CRD) and expanding into other mental health conditions. Chief Innovation Officer Dr. Peter Facchini noted the use of their PsyAI™ technology in molecule design. These molecules, synthesized for safety evaluation, may advance to preclinical development soon. The application aims to address significant psychological distress in cancer patients, where existing treatments have shown limited efficacy.